Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accumulated Expenses (2020 - 2025)

Foghorn Therapeutics has reported Accumulated Expenses over the past 6 years, most recently at $11.4 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $11.4 million for Q4 2025, up 33.13% from a year ago — trailing twelve months through Dec 2025 was $11.4 million (up 33.13% YoY), and the annual figure for FY2025 was $11.4 million, up 33.13%.
  • Accumulated Expenses for Q4 2025 was $11.4 million at Foghorn Therapeutics, up from $9.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for FHTX hit a ceiling of $11.4 million in Q4 2025 and a floor of $5.1 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $8.6 million (2025), compared with a mean of $8.4 million.
  • Biggest five-year swings in Accumulated Expenses: soared 57.14% in 2022 and later fell 29.06% in 2024.
  • Foghorn Therapeutics' Accumulated Expenses stood at $9.6 million in 2021, then grew by 15.05% to $11.0 million in 2022, then decreased by 17.21% to $9.1 million in 2023, then fell by 6.34% to $8.5 million in 2024, then soared by 33.13% to $11.4 million in 2025.
  • The last three reported values for Accumulated Expenses were $11.4 million (Q4 2025), $9.8 million (Q3 2025), and $8.6 million (Q2 2025) per Business Quant data.